Why Is EyePoint, Inc. (EYPT) Stock Down -69.80% Today?
Key Takeaways
- EYPT shares plunged 69.8% to $4.46 in early trading Monday, down from Friday's close of $14.75.
- The selloff was triggered by Phase 3 LUGANO trial results showing DURAVYU missed its primary endpoint in the full study dataset.
- The company attributed the miss to a small subgroup of patients who experienced vision loss unrelated to wet age-related macular degeneration.
- Positive secondary endpoints, including a 42% reduction in treatment burden, failed to offset investor concerns about the primary efficacy result.
- Broader equity and biotech indexes were little changed, confirming the decline was company-specific rather than market-driven.
- Traders are now watching for topline data from the LUCIA trial expected in the fourth quarter of 2026.
Opening Summary
EyePoint, Inc. (EYPT), a clinical-stage biopharmaceutical company focused on sustained-release treatments for serious retinal diseases, saw its stock collapse in early trading Monday. As of 9:38 a.m. ET, shares were trading at $4.46, down 69.8% from the previous close of $14.75. The move followed topline results from the Phase 3 LUGANO trial of DURAVYU in wet age-related macular degeneration, or wet AMD. Trading in the stock was halted in premarket action before shares reopened sharply lower at the start of the regular session.
Catalyst: Phase 3 LUGANO Trial Misses Primary Endpoint
The market reaction centered on a single clinical disclosure. EyePoint reported that the LUGANO trial did not meet its primary endpoint of change from baseline in best corrected visual acuity, or BCVA, versus a 2 mg aflibercept control in the full study dataset. The company said the result was confounded by an asymmetric cohort representing about 4% of the roughly 211-patient study, or approximately nine patients, who experienced vision loss of 15 letters or more for reasons unrelated to wet AMD. No patients in the aflibercept control arm experienced that type of non-wet-AMD-related vision loss.
In an ad hoc analysis excluding that subgroup, DURAVYU was non-inferior to on-label aflibercept, with a nominal p-value of 0.0096. However, the pre-specified primary endpoint miss in the complete dataset represents a meaningful setback for the lead pipeline program, and investors responded accordingly.
Secondary Endpoints Provide Support but Fail to Stem the Selloff
EyePoint emphasized clinically meaningful secondary outcomes from the LUGANO trial. The company highlighted a 42% reduction in treatment burden versus on-label aflibercept, with statistical superiority and a nominal p-value below 0.0001. Additional data showed high supplement-free rates, a favorable safety profile with redosing, and strong anatomic control through week 56.
Despite those findings, the market focused on the primary endpoint failure. For a pivotal registration program, a miss in the full analysis set remains the headline efficacy event, and ad hoc analyses generally require regulatory scrutiny before they can support an approval path.
Market Context and Trading Activity
After the premarket halt, EYPT reopened under intense selling pressure. Trading volume was heavy in the opening minutes, with roughly 400,000 shares changing hands in the first observable minute of resumed trading, a pace far above typical daily turnover. The decline took the stock well below its prior 52-week low near $9.65 and far beneath its 50-day and 200-day moving averages, which were both in the low-to-mid $13 range before the session.
Broader market conditions did not drive the move. Major U.S. equity benchmarks and biotech-tracking indexes were little changed in early trading Monday, underscoring that the collapse in EYPT reflected company-specific clinical news rather than a sector-wide or macroeconomic selloff.
What Comes Next for EYPT
Investor attention now shifts to the LUCIA trial, the second pivotal Phase 3 study of DURAVYU in wet AMD. Topline data are expected in the fourth quarter of 2026, with a potential FDA New Drug Application submission planned for the first half of 2027. The company is also advancing DURAVYU in diabetic macular edema.
Key uncertainties remain. Regulators may require additional evidence before accepting an ad hoc analysis as supportive of efficacy, and the LUCIA readout will be critical in determining whether the program can move forward. Analysts and investors will also be watching for any updated regulatory guidance and the company's capital position as the next data catalyst approaches.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI trading bots that are currently among the strongest performers under live market conditions. Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, with strategies that vary by timeframe, performance metrics, and traded symbols. Traders exploring systematic, data-driven approaches can use this section to discover which bot strategies are currently gaining traction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
EYPT's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for EYPT turned positive on August 07, 2026. Looking at past instances where EYPT's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on EYPT as a result. In of 72 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
EYPT moved above its 50-day moving average on August 12, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where EYPT advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for EYPT crossed bearishly below the 50-day moving average on July 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EYPT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
EYPT broke above its upper Bollinger Band on August 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EYPT entered a downward trend on August 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EYPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.639) is normal, around the industry mean (20.042). P/E Ratio (0.000) is within average values for comparable stocks, (24.309). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.844). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (434.783) is also within normal values, averaging (438.430).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EYPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of ophthalmic pharmaceuticals
Industry Biotechnology
Advertisement